Brii Biosciences Limited
BRIBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $668,639 | $1,188,022 | $4,740,474 | $7,669,394 |
| - Cash | $1,003,365 | $489,650 | $1,190,572 | $2,855,093 |
| + Debt | $28,020 | $3,156 | $12,656 | $21,616 |
| Enterprise Value | -$306,706 | $701,528 | $3,562,558 | $4,835,917 |
| Revenue | $49,936 | $617 | $51,626 | $92,542 |
| % Growth | 7,993.4% | -98.8% | -44.2% | – |
| Gross Profit | $49,936 | $617 | $51,626 | $92,542 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$401,609 | -$168,202 | -$503,584 | -$602,799 |
| % Margin | -804.2% | -27,261.3% | -975.4% | -651.4% |
| Net Income | -$508,162 | -$174,829 | -$484,312 | -$4,120,229 |
| % Margin | -1,017.6% | -28,335.3% | -938.1% | -4,452.3% |
| EPS Diluted | -0.7 | -0.24 | -0.67 | -9.48 |
| % Growth | -191.7% | 64.2% | 92.9% | – |
| Operating Cash Flow | -$372,890 | -$594,014 | -$496,279 | -$879,457 |
| Capital Expenditures | -$3,228 | -$49,608 | -$139,292 | -$1,029 |
| Free Cash Flow | -$376,118 | -$643,622 | -$635,571 | -$880,486 |